The Role of p38 MAPK in the Aetiopathogenesis of Psoriasis and Psoriatic Arthritis

Table 1

Innate and adaptive immunity mediators likely to be involved in psoriasis and psoriatic arthritis.

Psoriasis	Psoriatic arthritis
(i) Prominent lymphocytic infiltrate present in skin	(i) Prominent lymphocytic infiltrate present in joints
(i) TH1, TH17, TH22, NK, NKT, B cells; (ii) Dendritic cells, macrophages	(i) TH1, TH17, TH22, NK?, NKT?, B cells; (ii) Dendritic cells, macrophages?
(i) IL-12, IL-23, TNF-A, IFN-𝛾	(i) IL-12, IL-23, TNF-A, IFN-𝛾
(i) IL-6, IL-17A, IL-17F, IL-21, IL-22, IL-26, IL-27; (ii) Cathepsin K, psoriasin; (iii) Keratin 17; (iv) Plasma YKL-40?; (v) Purinergic receptor P2X7; (vi) Trem 1	(i) IL-6, IL-17A, IL-17F, IL-21, IL-22, IL-26, IL-27; (ii) Cathepsin K?, psoriasin?; (iii) Keratin 17?; (iv) Plasma YKL-40; (v) Purinergic receptor P2X7?; (vi) Trem 1?
(i) MAP kinases ERK1/2, JNK, P38; (ii) MK2, DUSP-1 MSK-1, GSK-3𝛽; (iii) NFKB, JAK/STAT-3, CREB	(i) MAP kinases ERK1/2, JNK, P38?; (ii) MK2?, DUSP-1?, MSK-1, GSK-3𝛽?; (iii) NFKB, JAK/STAT-3?, CREB

Question marks indicate inadequate data.